

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address (\*\* MMISS) (NEK - # PATENTS AND TRADEMARKS Washington DOT 2 2001 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09 867,845	0	05 29 2001	Chaitan Khosla	300622005500	7453
25225	7590	01-13-2003			
MORRISON & FOERSTER LLP				EXAMINER	
3811 VALLEY CENTRE DRIVE SUITE 500				ZHOU, SHUBO	
SAN DIEGO, CA 92130-2332		Γ	ART UNIT	PAPER NUMBER	
				1631	
				DATE MAILED: 01/13/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/867845			300622005500

09/159518

L

EXAMINER

Michael Borin

ART UNIT PAPER NUMBER

1631 18

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotides and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). See 37 CFR 1.821 (d). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reasons set forth on the attached Raw Sequence Listing Error Report.

Any inquiry concerning this communication should be directed to Examiner M.L. Borin, Art Unit 1631 whose telephone number is (703) 305-4506.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

MICHAEL BORIN, PH.D. PRIMARY EXAMINER

librar

Application No.:09/867845

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). A paper copy is in the file but is not in accordance with new Sequence Listing Rules. 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, X content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing.' 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: \_\_\_\_ Applicant Must Provide: A substitute computer readable form (CRF) copy of the "Sequence Listing". X An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.  $\overline{|\chi|}$  A statement that the content of the paper and computer readable copies are the same and. where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

For CRF Submission Help, call (703) 308-4212 For Patentln software help, call (703) 308-6856